Know Cancer

forgot password

A Phase I Study of LBH589 in Combination With Gemcitabine in the Treatment of Solid Tumors

Phase 1
18 Years
Not Enrolling
Solid Tumors

Thank you

Trial Information

A Phase I Study of LBH589 in Combination With Gemcitabine in the Treatment of Solid Tumors

Inclusion Criteria:

1. Histologically documented metastatic or locally advanced, incurable malignancy for
which gemcitabine is clinically appropriate (e.g., non-small cell lung cancer,
breast, ovarian, bladder cancer and lymphoma).

2. Male or female patients aged ≥ 18 years old.

3. Maximum of 3 prior regimens in a metastatic setting allowed and may include other
targeted agents, immunotherapy and chemotherapy.

4. Measurable disease by RECIST criteria.

5. ECOG PS 0 or 1.

6. Laboratory values as follows:

- ANC > 1500/μL

- Hgb > 9 g/dL

- Platelets >100,000/uL

- Bilirubin < 1.5 mg/dL

- AST/SGOT and ALT/SGPT < 2.5 x ULN or < 5.0 x ULN in patients with liver

- Creatinine < 2.0 mg/dL Or 24-hour Creatinine Clearance > 50 ml/min

- Albumin > 3 g/dL

- Potassium > lower limit normal (LLN)

- Phosphorous > LLN

- Calcium > LLN

- Magnesium > LLN

8. Women of childbearing potential must have a negative serum or urine pregnancy test
performed within 7 days prior to start of treatment. 9. Life expectancy > 12 weeks. 10.
Accessible for treatment and follow-up. 11. All patients must be able to understand the
nature of the study and be given written informed consent prior to study entry.

Exclusion Criteria:

1. Prior HDAC, DAC, HSP90 inhibitors or valproic acid for the treatment of cancer.
Patients who will need valproic acid for any medical condition during the study or
within 5 days prior to first LBH589 treatment

2. Impaired cardiac function including any of the following:

- Screening ECG with a QTc > 450 msec.

- Congenital long QT syndrome.

- History of sustained ventricular tachycardia.

- Any history of ventricular fibrillation or torsades de pointes.

- Bradycardia defined as heart rate < 50 beats per minutes. Patients wit a
pacemaker and heart rate > 50 beats per minute are eligible.

- Myocardial infarction or unstable angina within 6 months of study entry.

- Congestive heart failure (NY Heart Association class III or IV.

- Right bundle branch block and left anterior hemiblock (bifasicular block).

- Atrial fibrillation or flutter.

3. Uncontrolled hypertension (systolic blood pressure [BP] 180 or diastolic BP >100mm
Hg) or uncontrolled cardiac arrhythmias.

4. Active CNS disease, including meningeal metastases.

5. Known diagnosis of human immunodeficiency virus (HIV) infection.

6. Unresolved diarrhea > CTCAE grade 1.

7. Chemotherapy, investigational drug therapy, major surgery < 4 weeks prior to starting
study drug or patients that have not recovered from side effects of previous therapy.

8. Patient is < 5 years free of another primary malignancy except if the other primary
malignancy is not currently clinically significant or requiring active intervention,
or if other primary malignancy is a basal cell skin cancer or a cervical carcinoma in
situ. Existence of any other malignant disease is not allowed.

9. Concomitant use of any anti-cancer therapy or radiation therapy other than protocol
required gemcitabine.

10. Women who are pregnant or breast feeding or women of childbearing potential (WOCBP)
not willing to use a double barrier method of contraception during the study and 3
months after the end of treatment. One of these methods of contraception must be a
barrier method. WOCBP are defined as sexually mature women who have not undergone a
hysterectomy or who have not been naturally postmenopausal for at least 12
consecutive months (i.e., who has had menses any time in the preceding 12 consecutive
months). Women of childbearing potential (WOCBP) must have a negative serum or urine
pregnancy test within 7 days of the first administration of oral LBH589.

11. Male patients whose sexual partners are WOCBP not using a double method of
contraception during the study and 3 months after the end of treatment. One of these
methods must be a condom.

12. Patients with gastrointestinal (GI) tract disease, causing the inability to take oral
medication, malabsorption syndrome, a requirement for intravenous (IV) alimentation,
prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease
(e.g., Crohn's disease, ulcerative colitis).

13. Other concurrent severe, uncontrolled infection or intercurrent illness, including
but not limited to ongoing or active infection, symptomatic congestive heart failure,
unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social
situations that would limit compliance with study requirements.

14. Patients with uncontrolled coagulopathy.

15. Abnormal thyroid function (TSH or free T4) detected at screening. Patients with known
hypothyroidism who are stable on thyroid replacement are eligible.

Type of Study:


Study Design:

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To determine the maximum tolerated doses and dose limiting toxicities of LBH589 in combination with gemcitabine when administered to patients with advanced incurable malignant solid tumors.

Outcome Time Frame:

18 months

Safety Issue:


Principal Investigator

Howard Burris, M.D.

Investigator Role:

Study Chair

Investigator Affiliation:

Sarah Cannon Research Institute


United States: Food and Drug Administration

Study ID:




Start Date:

November 2007

Completion Date:

November 2009

Related Keywords:

  • Solid Tumors
  • Solid Tumors
  • Phase I
  • LBH589
  • Gemcitabine
  • Neoplasms



Tennessee Oncology, PLLC Clarksville, Tennessee  37043